Scott S. Tykodi

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

Life Sciences, Immunology, Oncology +17

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 780 citations · Full text

Medicine, Oncology, Pharmacology +12

Alterations of immune response of non-small cell lung cancer with Azacytidine

John Wrangle, Wei Wang, Alexander Koch et al. · Oncotarget · 2013 · 389 citations · Full text

Life Sciences, Immunology, Oncology +17

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George et al. · Cancer · 2020 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17